This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: Intracranial in-stent restenosis (ISR) remains an important complication after intracranial stenting, and validated preoperative biomarkers for subsequent ISR are lacking. In this exploratory study, we aimed to characterize preoperative plasma metabolic profiles associated with subsequent intracranial ISR and to assess their discriminatory performance in the internal validation subset. METHODS: We conducted a single-center, age- and sex-frequency-matched case-control study of 96 patients with ISR and 96 non-ISR controls selected from 285 eligible patients who underwent intracranial stenting. Untargeted liquid chromatography-mass spectrometry metabolomics was performed in a discovery subset (30 ISR and 30 non-ISR), followed by targeted ultra-performance liquid chromatography-tandem mass spectrometry quantification in the remaining nonoverlapping subset (66 ISR and 66 non-ISR). All plasma samples were obtained before stent implantation. RESULTS: Untargeted profiling identified preoperative metabolic differences spanning amino acid/peptide, lipid/membrane, bile acid, and nucleotide/redox domains, with amino acid-related differences prominently represented. Targeted analysis showed lower citrulline, phenylalanine, glycine, isoleucine, glutamine, and valine and higher ornithine and cystine in ISR. Citrulline showed the strongest single-metabolite discrimination (area under the curve [AUC] 0.860, 95% CI 0.794-0.926), whereas a citrulline-phenylalanine-ornithine panel achieved an AUC of 0.911 (95% CI 0.865-0.958) and a cross-validated AUC of 0.895. Several metabolites remained associated with ISR after adjustment for clinical covariates. CONCLUSIONS: Preoperative plasma metabolic profiles differed between patients who did and did not subsequently develop intracranial ISR. In the targeted stage, lower citrulline together with higher ornithine was the most prominent finding. These associations are hypothesis-generating, and the identified metabolites should be considered candidate biomarkers requiring independent prospective validation before clinical use.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: